

09/405,046

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:sssptal208dxj
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

NEWS EXPRESS April 18 CURRENT WINDOWS VERSION IS V6.0,
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
AND CURRENT DISCOVER FILE IS DATED 04/06

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:18:35 ON 07 MAY 2001

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 13:18:39 ON 07 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 6 MAY 2001 HIGHEST RN 334720-68-2
DICTIONARY FILE UPDATES: 6 MAY 2001 HIGHEST RN 334720-68-2

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

09/405,046

Structure search limits have been increased. See HELP SLIMIT
for details.

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\peptide.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d

L2 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L2 QUE ABB=ON PLU=ON L1

=> s 12

SAMPLE SEARCH INITIATED 13:19:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 104 TO ITERATE

100.0% PROCESSED 104 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1469 TO 2691

PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\peptide.str

L4 STRUCTURE UPLOADED

=> que L4

L5 QUE L4

=> d

L5 HAS NO ANSWERS

09/405,046

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L5 QUE ABB=ON PLU=ON L4

=> s 15

SAMPLE SEARCH INITIATED 13:19:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 104 TO ITERATE

100.0% PROCESSED 104 ITERATIONS

28 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1469 TO 2691
PROJECTED ANSWERS: 243 TO 877

L6 28 SEA SSS SAM L4

=> fil .search

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.62	0.77

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 13:20:00 ON 07 MAY 2001

FILE 'CAPLUS' ENTERED AT 13:20:00 ON 07 MAY 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:20:00 ON 07 MAY 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'USPATFULL' ENTERED AT 13:20:00 ON 07 MAY 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:20:00 ON 07 MAY 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

=> s 16 and (polypeptide? or peptide?)
L7 8 L6 AND (POLYPEPTIDE? OR PEPTIDE?)

=> dup rem 17

PROCESSING COMPLETED FOR L7

L8 8 DUP REM L7 (0 DUPLICATES REMOVED)

=> d ibib ab 1-

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):Y

09/405,046

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:421115 CAPLUS
DOCUMENT NUMBER: 133:59101
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Cheesman, Edward H.; Sworin, Michael; Rajopadhye, Milind
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Co., USA
SOURCE: PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035887	A2	20000622	WO 1999-US30311	19991217
WO 2000035887	A3	20001116		

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1998-112831 P 19981218
OTHER SOURCE(S): HARPAT 133:59101
AB Comps. (Q)d-Ln-Ch (Q is a residue having a benzodiazepine-, benzodiazepinedione-, or dibenzotrihydroannulene-type moiety, d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, (S,S,S)-4-[N-[3-[3,6-diaza-10-[N-(benzimidazol-2-ylmethyl)-N-methylcarbamoyl]-5-(carboxymethyl)-4-oxobicyclo[5.4.0]undeca-1(7),8,10-trien-3-yl]propyl]carbamoyl]-4-[[[4-carboxy-2-[2-[1,4,7,10-tetraaza-4,7,10-tris(carboxymethyl)cyclodecyl]acetylaminobutanoyl]amino]butanoic acid was prepd. (claimed compd.). Syntheses of radiopharmaceuticals, e.g., ^{99m}Tc(VnA) (tricine) (phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:420991 CAPLUS
DOCUMENT NUMBER: 133:59098
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Rajopadhye, Milind; Harris, Thomas David; Cheesman, Edward H.
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 362 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035488	A2	20000622	WO 1999-US30312	19991217
WO 2000035488	A3	20001109		

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1998-112829 P 19981218
OTHER SOURCE(S): HARPAT 133:59098
AB Comps. (Q)d-Ln-Ch (Q is a residue having an indazole-type moiety, d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, 2-[[[4-[4-[[[3-[2-[2-[3-[6-[[[1-aza-2-(2-sulfonylphenyl)vinyl]amino](3-pyridyl)]carbonylamino]propoxy]ethoxy]ethoxy]propyl]amino]sulfonyl]phenyl]phenyl]sulfonyl]amino]-3-[[[1-[3-(indazole-2-ylamino)propyl](1H-indazol-5-yl)]carbonylamino]propanoic acid was prepd. (claimed compd.). Syntheses of radiopharmaceuticals, e.g., ^{99m}Tc(VnA) (tricine) (phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:420994 CAPLUS
DOCUMENT NUMBER: 133:59099
TITLE: Preparation of vitronectin receptor antagonist pharmaceuticals
INVENTOR(S): Harris, Thomas David; Rajopadhye, Milind
PATENT ASSIGNEE(S): Du Pont Pharmaceuticals Company, USA
SOURCE: PCT Int. Appl., 300 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035492	A2	20000622	WO 1999-US30315	19991217
WO 2000035492	A3	20010118		

W: AL, AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MK, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPLN. INFO.: US 1998-112732 P 19981218
OTHER SOURCE(S): HARPAT 133:59099
AB Comps. (Q)d-Ln-Ch (Q is a residue having a quinolone-type moiety, d = 1-10, Ln is a linking group, Ch is a metal-bonding unit) were prepd. for use in the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compds. useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. Thus, [3-[1-[3-[3-[N-[3-[2-[N-(L-Asp-L-Asp)-3-aminopropoxy]ethoxy]ethoxy]propyl]carbamoyl]propanoylamino]propyl]-7-[[[imidazol-2-ylamino]methyl]-4-oxo-3-hydroquinolyl]carbonylamino]-2-[[[2,4,6-trimethylphenyl]sulfonyl]amino]propanoic acid DOTA conjugate was prepd. (claimed compd.). Syntheses of radiopharmaceuticals, e.g., ^{99m}Tc(VnA) (tricine) (phosphine), where VnA represents the vitronectin receptor antagonist, are also described.

L8 ANSWER 4 OF 8 USPATFULL
ACCESSION NUMBER: 2000:94681 USPATFULL
TITLE: Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
INVENTOR(S): Vedeking, Paul W., Pennington, NJ, United States
Wager, Ruth E., Rockville, MD, United States
Arunachalam, Thangavel, Plainsboro, NJ, United States
States
Ramalingam, Kondareddi, Dayton, NJ, United States
Linder, Karen E., Kingston, NJ, United States
Ranganathan, Ramachandran S., Princeton, NJ, United States
Nunn, Adrian D., Lambertville, NJ, United States
Raju, Natarajan, Kendall Park, NJ, United States
Tweedle, Michael F., Princeton, NJ, United States
Bracco Research USA Inc., Princeton, NJ, United States
PATENT ASSIGNEE(S): States
(U.S. corporation)

NUMBER	DATE
US 6093382	20000725
US 1998-80157	19980516 (9)

PATENT INFORMATION:
APPLICATION INFO.: Utility
DOCUMENT TYPE: Dees, Jose' G.
PRIMARY EXAMINER: Jones, Dameron
ASSISTANT EXAMINER: Balogh, Iare
LEGAL REPRESENTATIVE: 36
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 8 Drawing Figure(s); 8 Drawing Page(s)
NUMBER OF DRAWINGS: 3756
LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Diagnostic and therapeutic compositions in the form of complexes for enhancing transmembrane transport of a diagnostic or therapeutic agent and methods for their use. The complexes contain the .alpha., .gamma., or bis isomers of folate receptor-binding analogs of folate, a metal chelated by a ligand, and in one embodiment, a chemotherapeutic agent.

09/405,046

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1997:377856 CAPLUS
 DOCUMENT NUMBER: 126:343881
 TITLE: Preparation of magnetically labeled peptide
 chemoattractants as targeted contrast agents in
 the
 INVENTOR(S): NMR imaging of living tissues
 Stephen Tweedle, Michael F.; Kumar, Krishan; Eaton,
 PATENT ASSIGNEE(S): Bracco International B.V., Neth.
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9714443	A1	19970424	WO 1996-1B1103	19961018
W: JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
PT, SE				
EP 814849	A1	19980107	EP 1996-932764	19961018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,				
PT,				
IE, FI				
JP 10511701	T2	19981110	JP 1996-515662	19961018
US 1995-5669 19951019				
WO 1996-1B1103 19961018				
PRIORITY APPLN. INFO.:				
AB The present invention addresses magnetically labeled chemoattractants, e.g. chemotactic peptides, for the detection and investigation of diseased or disordered tissue sites or organs in the body of human and animal patients. The chemotactic peptides have the general formula N(X)-Y-Leu-Phe-Z-A-W [(X) = H, protective group such as OHC, Ac, Me3CO2C (Boc), or the like; Y = Nle, Met; Z = bond, amino acid, oligopeptide, e.g. N-epsilon-Lys, Ile, Asp, Nle-Tyr-N-epsilon-Lys, (Gly)n, n = 1-4; A = linker; W = suitably derivatized paramagnetic macrocyclic chelate or magnetic particle). The invention also concerns physiol. acceptable administrable compns. of formulations comprising the labeled chemoattractants, methods for prepg. the chemoattractants and the formulations, and methods of using the formulations for detecting, localizing and diagnosing infected or inflammatory sites, or other trauma in the organism. Thus, amidation of chemotactic peptide OHC-Met-Leu-Phe-OH with macrocycle I (R = H) (prepn. given) gave 401 of peptide macrocycle I (R = OHC-Met-Leu-Phe), which reacted with				

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2001 ACS (Continued)
 GdCl3 in water at pH 7 at 60.degree. to give 80% of the corresponding
 monogadolium salt.

L8 ANSWER 6 OF 8 USPATFULL
 ACCESSION NUMBER: 95:58256 USPATFULL
 TITLE: Complexes of functionalized tetraazacyclododecane
 chelates with bismuth, lead, yttrium, actinium, or
 lanthanide metal ions
 INVENTOR(S): Gansow, Otto A., Washington, DC, United States
 Brechbiel, Martin W., Annandale, VA, United States
 Magretz, Michael A., Hofheim, Germany, Federal
 Republic of
 PATENT ASSIGNEE(S): The United States of America as represented by the
 Department of Health and Human Services,
 Washington,
 DC, United States (U.S. government)
 NUMBER DATE
 PATENT INFORMATION: US 5429154 19950627
 APPLICATION INFO.: US 1993-140714 19931022 (8)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-815956, filed on
 2 Jan 1992, now abandoned which is a continuation of
 Ser. No. US 1988-198538, filed on 25 May 1988, now abandoned
 DOCUMENT TYPE: Utility
 PRIMARY EXAMINER: Higley, Floyd D.
 LEGAL REPRESENTATIVE: Leydig, Voit & Mayer, Ltd.
 NUMBER OF CLAIMS: 8
 EXEMPLARY CLAIMS: 1
 LINE COUNT: 448
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention is a chelate of formula I: ##STR1## wherein R.sub.1-4
 is

--CH.sub.2 COOH;
 n is 1 to 5;
 X is a member selected from the group consisting of
 --NO.sub.2,
 --NH.sub.2,
 --NCS,
 --NHCOCH.sub.2 --Z, with Z being a member selected from the group
 consisting of Br and I,
 --COOH; and
 --OCH.sub.2 OCH;
 and M is a metal ion selected from the group of elements consisting
 of

Bi, Pb, Y, Cd, Hg, Al, Th, Sr, and Lanthanides.

The invention also includes a chelate, wherein M is a copper ion
 and n

L8 ANSWER 6 OF 8 USPATFULL (Continued)
 is an integer from 2 to 5. The invention includes chelate
 conjugates of
 formula I and ligand conjugates of formula II: ##STR2## The
 invention
 also includes methods to use these compounds for treatment of
 cellular
 disorders and for diagnostic tests.

09/405,046

L8 ANSWER 7 OF 8 USPATFULL

ACCESSION NUMBER: 94:99669 USPATFULL
TITLE: Polychelants containing macrocyclic chelant
moieties
INVENTOR(S): Sieving, Paul F., 3166 Impala Dr. #5, San Jose, CA,
United States 95117
Watson, Alan D., 262A Rincon Ave., Campbell, CA,
United States 95008

Quay, Steven C., 428 Oakmead Pkwy., Sunnyvale, CA,
United States 94086
Rocklage, Scott M., 255 Cresci Rd., Los Gatos, CA,
United States 95030

	NUMBER	DATE
PATENT INFORMATION:	US 5364613	19941115
APPLICATION INFO.:	US 1990-464865	19900116 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1989-335162, filed	

on 7 Apr 1989, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Michl, Paul R.
ASSISTANT EXAMINER: Yoon, Tae H.
LEGAL REPRESENTATIVE: Lyon & Lyon

NUMBER OF CLAIMS: 33
EXEMPLARY CLAIMS: 1
LINE COUNT: 1352

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are provided polychelants and their metal chelates which are
useful in diagnostic imaging and in radiotherapy and which comprise

a plurality of macrocyclic chelant moieties, e.g. DOTA residues,
conjugated to a polyamine backbone molecule, e.g. polylysine. To

produce a site-specific polychelate, one or more of the macrocyclic chelant
carrying backbone molecules may be conjugated to a site-directed
macromolecule, e.g. a protein.

L8 ANSWER 8 OF 8 USPATFULL

ACCESSION NUMBER: 92:61733 USPATFULL
TITLE: Radiolabeled metal-binding protein for the
treatment of

arthritis
INVENTOR(S): Garlich, Joseph R., Lake Jackson, TX, United States
McMillan, Kenneth, Richwood, TX, United States
Simon, Jaime, Angleton, TX, United States
The Dow Chemical Company, Midland, MI, United
States

(U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5133956	19920728
APPLICATION INFO.:	US 1991-707719	19910530 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Stoll, Robert L.	
ASSISTANT EXAMINER:	Sayals, C.	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
LINE COUNT:	462	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Radioactive high molecular weight metal-binding protein
compositions and

a method for therapeutic radiation treatment including the
treatment of

rheumatoid arthritis comprising injection of a radioactive high
molecular weight metal-binding protein compositions are disclosed.